Baird Financial Group
MRNS

Baird Financial Group’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Baird Financial Group’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-3,916
Closed -$24K – 1564
2019
Q3 		$24K Sell
3,916
-125
-3% -$1.01K ﹤0.01% 1497
2019
Q2 		$67K Hold
4,041
– – ﹤0.01% 1510
2019
Q1 		$68K Sell
4,041
-500
-11% -$7.2K ﹤0.01% 1274
2018
Q4 		$52K Buy
+4,541
New +$91.9K ﹤0.01% 1256

Other funds holding MRNS

LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Baird Financial Group's MRNS Position: Q4 2019 in Review

Baird Financial Group sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q4 2019, closing a stake of 3,916 shares — an estimated $24K sold.

Baird Financial Group first reported a position in MRNS in Q4 2018 and held it in 4 quarters. The position peaked at $68K in Q1 2019. 79 funds tracked by Wall St. Rank hold MRNS as of Q4 2019.

  • Baird Financial Group reported no remaining Marinus Pharmaceuticals, Inc position as of Q4 2019 after selling out during the quarter.
  • Baird Financial Group sold 3,916 Marinus Pharmaceuticals, Inc shares in Q4 2019, an estimated $24K.
  • Baird Financial Group first reported a position in Marinus Pharmaceuticals, Inc in Q4 2018 and held it in 4 quarters.
  • Baird Financial Group's Marinus Pharmaceuticals, Inc position peaked at $68K in Q1 2019.
  • 79 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q4 2019.

Based on Baird Financial Group's 13F filing for Q4 2019, filed 14 Feb 2020.